 TUCSON, Ariz., Dec. 18, 2020 GLOBE NEWSWIRE -- HTG Molecular Diagnostics, Inc. Nasdaq: HTGM HTG, a life science company whose mission is to advance precision medicine, today announced that it has signed up the first collaborator in its recently announced Early Access Program for its prototype whole transcriptome panel. The Early Access Program is intended to allow select customers access to the panel in their laboratories or through services to be performed in our development laboratory prior to commercial launch of this product. 